interferon γ-1b
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Friedreich's Ataxia
Conditions
Friedreich's Ataxia
Trial Timeline
Jun 28, 2016 → Mar 31, 2017
NCT ID
NCT02797080About interferon γ-1b
interferon γ-1b is a phase 3 stage product being developed by Amgen for Friedreich's Ataxia. The current trial status is completed. This product is registered under clinical trial identifier NCT02797080. Target conditions include Friedreich's Ataxia.
What happened to similar drugs?
0 of 6 similar drugs in Friedreich's Ataxia were approved
Approved (0) Terminated (0) Active (6)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02797080 | Phase 3 | Completed |
| NCT02593773 | Phase 3 | Completed |
Competing Products
11 competing products in Friedreich's Ataxia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Interferon γ-1b | Amgen | Phase 3 | 40 |
| Interferon γ-1b + Placebo | Amgen | Phase 3 | 40 |
| varenicline + placebo | Pfizer | Phase 2/3 | 30 |
| Lu AA24493 + Placebo | Lundbeck | Phase 2 | 32 |
| Omeveloxolone | Biogen | Pre-clinical | 30 |
| Placebo + EPI-743 400 mg + EPI-743 200 mg | PTC Therapeutics | Phase 2 | 32 |
| SGT-212 | Solid Biosciences | Phase 1 | 30 |
| idebenone + Placebo | Santhera Pharmaceuticals | Phase 3 | 30 |
| Idebenone + Idebenone + Placebo | Santhera Pharmaceuticals | Phase 3 | 30 |
| Idebenone | Santhera Pharmaceuticals | Phase 3 | 30 |
| Idebenone + Placebo | Santhera Pharmaceuticals | Phase 3 | 30 |